Floatz Rating
B58/100
Confidence
Indicative
Sponsor
MOMA Therapeutics
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
57High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06545942CT.gov Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT05807126CT.gov Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations | — | Withdrawn | — | — | — |
NCT06065059CT.gov Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors | — | Terminated | — | — | — |
NCT05568550CT.gov Pembro With Radiation With or Without Olaparib | — | Recruiting | — | — | — |
NCT05501548CT.gov Phase II Study of PARP Inhibitor Olaparib and IV Ascorbate in Castration Resistant Prostate Cancer | — | Terminated | — | — | — |
NCT05498272CT.gov Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations | — | Recruiting | — | — | — |
NCT06783127CT.gov Clinical Outcomes of Use of Olaparib in Castration Resistant Prostate Cancer | — | Recruiting | — | — | — |
NCT05252390CT.gov NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors | — | Terminated | — | — | — |
NCT05167175CT.gov The Study of Olaparib Combined With Abiraterone and Prednisone in mHSPC Patients With HRR Gene Mutation | — | Unknown | — | — | — |
NCT05262608CT.gov The Study of Olaparib in Newly Diagnosed mCRPC Patients With HRR Gene Mutation | — | Unknown | — | — | — |
Show 13 more trialsShow fewer
NCT04748042CT.gov Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON) | — | Active Not Recruiting | — | — | — |
NCT04586335CT.gov Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. | — | Terminated | — | — | — |
NCT03878524CT.gov Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | — | Terminated | — | — | — |
NCT03787680CT.gov Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial) | — | Active Not Recruiting | — | — | — |
NCT03810105CT.gov A Study of Olaparib and Durvalumab in Prostate Cancer | — | Terminated | — | — | — |
NCT03317392CT.gov Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis | — | Active Not Recruiting | — | — | — |
NCT03570476CT.gov Olaparib Before Surgery in Treating Participants With Localized Prostate Cancer | — | Terminated | — | — | — |
NCT03432897CT.gov BrUOG 337: Olaparib Prior to Radical Prostatectomy For Advanced Prostate Cancer Defects in DNA Repair Genes | — | Terminated | — | — | — |
NCT03263650CT.gov Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC | — | Completed | — | — | — |
NCT03205176CT.gov AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas | — | Completed | — | — | — |
NCT03012321CT.gov Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects | — | Active Not Recruiting | — | — | — |
NCT02324998CT.gov Study of Olaparib (± Degarelix) Given to Men With Intermediate/High Risk Prostate Cancer Before Prostatectomy | — | Completed | — | — | — |
NCT02769962CT.gov Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Prostate Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Olaparib (this asset) | MOMA Therapeutics | P2 | B · 58 |
| Avodart | Bay State Clinical Trials, Inc. | P4 | BBB |
| Desflurane | Peter MacCallum Cancer Centre, Australia | P4 | BBB |
| Propofol | Peter MacCallum Cancer Centre, Australia | P4 | BBB |
| Degarelix | Bayer | P4 | BBB |
| Flotufolastat F 18 | Washington University School of Medicine | P4 | BB |
| AVOLVE | Masonic Cancer Center, University of Minnesota | P4 | BB |
| Estramustine | The University of Texas Health Science Center, Houston | P3 | BB |
| Pasireotide | RECORDATI GROUP | P4 | BB |
+42 more in the Prostate Cancer cohort
Other indications for Olaparib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Breast Carcinoma | — | P4 | BBB · 73 |
| Fallopian Tube Serous Adenocarcinoma | — | P3 | BBB · 72 |
| Ovarian Carcinoma | — | P4 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Olaparib in Prostate Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 11, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/olaparib-prostate-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →